Background

Nucleic Acid Aptamers (Aptamers) are single-stranded DNA or RNA oligonucleotides. By folding into specific three-dimensional structures, Aptamers acquire high affinity and specificity for target molecules. Compared to traditional antibodies, Aptamers offer significant advantages: smaller molecular size, ease of synthesis and modification, lack of immunogenicity, high stability, and a broader range of potential targets. These advantages make Aptamers valuable in medical diagnostics, separation, and purification applications. The prerequisite for realizing these applications is the efficient and reliable acquisition of Aptamers targeting specific molecules. This guide details the complete synthesis Process for Nucleic Acid Aptamers.

Nucleic Acid Aptamer Screening

Target Selection and Library Design

Potential targets include proteins, small molecules, cells, and viral particles. The library design consists primarily of a random region flanked by fixed primer regions. The random region provides structural diversity, its core being a completely random nucleotide sequence (typically 20-80 nucleotides; its length determines library complexity). Fixed primer regions are designed at both ends of the random sequence for primer binding in subsequent PCR amplification.

To enhance Aptamer stability (especially for RNA aptamers), chemically modified nucleotides can be incorporated directly during library synthesis to prevent degradation. Sometimes, based on target properties or desired binding modes, specific sequence motifs (e.g., G-rich regions potentially forming G-quadruplexes, or stem sequences for hairpin structures) are embedded in the random region to guide library structure formation.

SELEX Screening

SELEX (Systematic Evolution of Ligands by EXponential Enrichment) simulates natural evolution. This process performs directed screening and enrichment of vast nucleic acid libraries in vitro to isolate a small number or even a single aptamer sequence with high affinity and specificity for the target.

Key steps [1]:

Fig 1 SELEX Screening Steps[1]

Incubation

The initial library is incubated with the target under specific conditions (buffer, temperature, time) to form aptamer-target complexes.

Partitioning

Sequences specifically bound to the target are separated from unbound sequences. Strict washing conditions are crucial to remove weak or non-specifically bound sequences. Common methods include immobilized target, filtration, and capillary electrophoresis.

Elution

Specifically bound sequences are recovered from the target using competitive elution, denaturing elution, or enzymatic cleavage.

Amplification

The eluted sequences are amplified by PCR or RT-PCR to generate a sufficient library quantity for the next round.

Screening Strategies and Optimization

Counter-Selection

Removes sequences binding to non-target molecules, enhancing specificity.

Increasing Stringency

Gradually increases screening rigor across rounds (e.g., reducing target concentration, increasing wash stringency, shortening binding time).

Monitoring

Tracks enrichment progress using methods like qPCR or gel electrophoresis to determine the optimal endpoint (typically 8-15 rounds).

Cloning, Sequencing and Analysis

SELEX yields an enriched mixture of sequences. Subsequent steps identify specific, representative individual candidate aptamers:

Cloning

The final enriched library is cloned into a bacterial plasmid vector, transformed into competent cells, and cultured to obtain single clones.

Sequencing

Dozens to hundreds of individual clones are selected for Sanger sequencing or High-throughput Sequencing (NGS).

Sequence Analysis

Involves sequence alignment, structural prediction, and conserved sequence analysis. This identifies repeated or highly similar sequences/families. Structural prediction determines secondary structures (stems, loops, bulges, G-quadruplexes), which often dictate binding specificity and affinity. Analyzing conserved nucleotide sequences or structural motifs across families identifies potential key binding regions[2].

Functional Validation and Characterization

Sequences identified through screening and sequencing must undergo rigorous experimental validation of binding performance and function:

Synthesis

Candidate sequences (often incorporating library modifications are chemically synthesized.

Affinity Measurement

Determines the dissociation constant (Kd) using methods like Surface Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC), Fluorescence Polarization (FP), or Electrophoretic Mobility Shift Assay (EMSA).

Specificity Assessment

Tests aptamer specificity against target analogs and non-target molecules.

Functional Testing

Evaluates aptamer performance in the intended application (e.g., inhibiting enzyme activity, blocking receptor binding, mediating cell targeting, or functioning as a sensor probe).

Critical Synthesis Factors

Target State

Target purity, activity, and homogeneity (especially protein conformation) are fundamental for screening success.

Screening Conditions

Simulating the actual application environment by varying buffer (pH, ionic strength), temperature, and time is crucial.

Library Bias

PCR amplification bias and fixed primer regions can introduce library distortion.

Sequence Optimization

Truncation, mutation or introducing additional modifications can enhance stability/affinity or reduce synthesis cost.

SELEX Technology Evolution

Techniques like Cell-SELEX and Microfluidic (Chip-SELEX), combined with NGS sequencing, significantly improve aptamer synthesis efficiency.

Summary and Outlook

Nucleic acid aptamer synthesis is a rigorous and precise experimental process.

Alpha Lifetech leverages Cell-SELEX, Microfluidics, and NGS sequencing to provide clients with Aptamer Screening Services that are faster and more accurate than traditional methods, ensuring high affinity and specificity.

FAQ

1. How should the initial ssDNA/RNA library be selected and prepared? What are the experimental considerations for random region length, library quantity, and chemical modifications?

(i)The random region is typically 30-50 nt long. Shorter regions (<20 nt) limit structural diversity, while longer regions (>80 nt) can form internal secondary structures, reducing the proportion of effective binding sites. Pre-testing libraries of different lengths for enrichment efficiency is recommended. Flanking primer regions must avoid sequences complementary to the random region, be 18-25 nt long (Tm ≥60°C), and ensure efficient PCR amplification.

(ii)Library theoretical diversity should reach 1013-1015 molecules. Synthetically, 1 nmol ssDNA library contains ~6×1014 molecules, covering most random sequence combinations. The initial library requires validation of sequence uniformity via high-throughput sequencing, with ≤3 PCR amplification cycles.

(iii)Chemical modifications can enhance stability. RNA libraries require 2'-fluoro/amino-methyl modifications for RNase resistance. DNA libraries can incorporate phosphorothioate bonds (PS modification) for enhanced nuclease resistance, though this may affect binding affinity. Functional group introduction (e.g., 5'/3' biotin for streptavidin-based solid-phase selection, or amino groups for subsequent conjugation) must control modification density to avoid steric hindrance.
2. During SELEX cycles, how can non-specific binding be effectively reduced and screening stringency increased? How are binding/wash conditions optimized?

(i)Optimize binding conditions via buffer composition and incubation parameters. Buffer composition: Na+/K+ salts modulate electrostatic interactions; Mg2+ salts stabilize nucleic acid structures. Add 0.01-0.1% Tween-20 (detergent) to reduce hydrophobic adsorption and 1-5% BSA or 0.1 mg/ml tRNA (blocking agents) to block non-specific sites. Incubation parameters: Adjust temperature (4-37°C) and time (15-60 min) based on target properties; use dynamic rotation to promote binding.

(ii)Optimize wash conditions by increasing wash stringency through progressively higher wash counts and longer durations per round. Introduce competitors (non-target molecules or low-affinity analogs) and implement negative selection steps (pre-incubating the library with non-target matrix to deplete cross-reactive sequences).
3. During PCR amplification of the enriched library, how can bias be avoided to obtain high-quality ssDNA/RNA for the next round?

Mitigate PCR bias through enzyme/program optimization and uniform amplification strategies. Enzyme/Program optimization: Use high-fidelity polymerase with proofreading; employ hot-start PCR to reduce primer dimers; limit cycle number. Uniform amplification strategies: Use touchdown PCR for specificity; add Betaine (1-3 M) or DMSO (3-5%) to disrupt secondary structures.

High-quality ssDNA/RNA preparation relies on strand separation techniques and purification validation:

(i) Biotin-Streptavidin Method: Capture biotinylated antisense strand with streptavidin beads, followed by alkaline elution.
(ii) Asymmetric PCR: Use excess sense primer (50:1 ratio) for direct ssDNA amplification.
(iii) Enzymatic Digestion: Incorporate ribonucleotides or dUTP for selective degradation by UNG/RNase H.

Validate purification via PAGE or capillary electrophoresis, confirming single-strand purity (OD260/280 ≈ 1.8-2.0).
4. After completing screening, how can cloning, sequencing, and preliminary sequence analysis be efficiently performed? How are potential aptamers identified from numerous sequences?

(i)Post-screening, subject the enriched library to cloning and deep analysis. Use TA cloning or seamless cloning into plasmids; verify insert size via colony PCR for at least 50 single colonies. For high-throughput sequencing, use the Illumina MiSeq platform (2×300 bp reads) with ≥100,000 reads per round depth.

(ii)Sequence analysis involves: FastQC for data quality assessment; Cutadapt for primer removal; clustering tools (e.g., FASTAptamer) for grouping by similarity.

(iii)Identify potential aptamers via multifaceted analysis: Calculate frequency ratio between final and initial rounds (>100-fold indicates significant enrichment); mine conserved motifs using MEME or GLAM2; predict secondary structures with RNAstructure (prioritizing stable structures with ΔG ≤ -5 kcal/mol and recurring motifs).
5. How can binding affinity (Kd) and specificity of positive clones be reliably validated? What are key experimental considerations for common methods (e.g., ELAA, SPR, BLI)?

Validate positive clones through dual assessment of binding affinity (Kd) and specificity.

(i) ELISA-like Assay (ELAA): Suitable for low sample volumes (pmol-level); coat target at >10x estimated Kd; avoid secondary antibody cross-reactivity.
(ii) Surface Plasmon Resonance (SPR): Detects pM-μM affinity; optimize flow rate (20-50 μL/min) and regeneration buffer (e.g., glycine pH 2.0-3.0).
(iii) Bio-Layer Interferometry (BLI): Requires stable baseline (>300 sec) and binding phase shaking (>1000 rpm).

Assess specificity via: Cross-reactivity testing (Kd ratio to analogs should be >10); competitive inhibition (>80% signal reduction with 100x free target); key site mutation validation (>5-fold Kd increase post-mutation). Perform all assays in triplicate, using buffers matching screening conditions; maintain constant temperature (25°C) for SPR/BLI to minimize drift.

reference

[1] Pandiyaraj K, Shahad A, Mohammed Z, et al. SELEX-derived DNA aptamer utilized for sensitive electrochemical biosensing of Toxoplasma gondii surface antigen 1[J]. International Journal of Biological Macromolecules, Volume 310, Part 4, 2025, 143530.

[2] Minchuan L, Chi H C, Ziqi C, et al. Advantages, applications, and future directions of in vivo aptamer SELEX: A review[J]. Molecular Therapy Nucleic Acids, Volume 36, Issue 3, 2025, 102575.

Nucleic Acid Aptamer Screening Protocol and FAQs